Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients

@article{Asnis2001FluvoxamineIT,
  title={Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients},
  author={Gregory M. Asnis and Faiq A. Hameedi and Andrew W. Goddard and Steven G. Potkin and Donald W. Black and Mustaq Jameel and Kishore Desagani and Scott W. Woods},
  journal={Psychiatry Research},
  year={2001},
  volume={103},
  pages={1-14}
}
Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the… Expand
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
Evaluating the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder found it efficacious, safe, and well tolerated in the treatment of panic disorder. Expand
Fluvoxamine in the treatment of anxiety disorders
  • J. Irons
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2005
TLDR
Fluvoxamine is a selective-serotonin reuptake inhibitor that has proved effective in large double-blind, randomized, controlled trials involving patients with social anxiety disorder, obsessive-compulsive disorder, and panic disorder and was the first SSRI to be registered for the treatment of OCD in children. Expand
Mirtazapine in the treatment of panic disorder: an open-label trial
TLDR
Mirtazapine was well tolerated as signified by the low discontinuation rate, and all patients showed a significant symptomatic improvement, and the improvement did not appear to be linked to the concurrent presence of a depressive illness. Expand
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies
TLDR
The authors explore the anxiolytic mechanism of action of this antidepressant drug class and the preclinical studies that are being developed to clarify the etiopathogenic mechanisms of PD and, more precisely, the role of the serotoninergic system in this pathogenesis. Expand
A Naturalistic Long-Term Comparison Study of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder
TLDR
Most of PD patients responded well to 12-month treatment with either citalopram, fluoxetine, fluvoxamine, or paroxetines, and the overall response rate was equal after the first 4 weeks of treatment. Expand
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study
TLDR
Low-dose risperidone appears to be an effective treatment for anxiety disorders in which panic attacks are a significant component and post hoc tests suggest that subjects receiving ris peridone may have a quicker clinical response than subjects receiving paroxetine. Expand
Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines
TLDR
Despite strong evidence of the effectiveness of SSRIs and benzodiazepines in the treatment of PD, few trials have performed head-to-head comparisons of these two drug classes, which could help improve the evidence-based pharmacotherapy of PD. Expand
Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment
TLDR
Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment, and clinical guidelines based on incontrovertible evidence are needed. Expand
Antidepressants versus placebo for panic disorder in adults.
TLDR
Low-quality evidence was found that revealed a benefit for antidepressants as a group in comparison with placebo in terms of efficacy measured as failure to respond, and treatment acceptability, measured by total number of dropouts for any reason. Expand
New treatment options for panic disorder: clinical trials from 2000 to 2010
TLDR
A systematic review of the literature regarding the pharmacological treatment of Panic disorder in the last 10 years found that SSRIs and SNRIs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
TLDR
Results support the safety and efficacy of sertraline for the short-term treatment of patients with panic disorder. Expand
Effect of fluvoxamine on panic disorder.
TLDR
The effects of fluvoxamine on anxiety, depressive mood, and disability differed from placebo only after 6 weeks of treatment, after which the placebo group showed either no further improvement or a reversal of symptoms. Expand
Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.
TLDR
Fluvoxamine was significantly more effective with regard to the diminution in the number of limited panic attacks and showed a tendency to significance in respect of GAS and CGI. Expand
Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation.
TLDR
Sertraline was effective and safe in reducing panic attacks and dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sERTraline. Expand
Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine.
TLDR
Both tricyclics and clomipramine were found to be markedly and equally effective for blocking panic attacks, alleviating phobic avoidance, and reducing nonspecific aspects of anxiety. Expand
A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
TLDR
Paroxetine produced significant improvements compared with placebo in various measurements of panic attack frequency, and was as effective as clomipramine, but appeared to have a more rapid onset of action than clomIPramine in reducing the number of panic attacks to zero. Expand
Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.
TLDR
The results support the hypothesis that brain serotonergic pathways are implicated in the pathophysiology of anxiety disorders, particularly in agoraphobia and panic disorders. Expand
Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response.
TLDR
Clonazepam-treated patients experienced significantly fewer panic attacks, and these were of lesser intensity and short duration than those in placebo-treatment patients (p < 0.001). Expand
A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.
TLDR
Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables and cognitive therapy was not superior to fluvoxamine on any rating. Expand
A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
TLDR
The selective and reversible MAO-A-I brofaromine and the SSRI fluvoxamine are equally effective in the treatment of PD and both compounds lead to a reduction in the number of panic attacks and a subsequent reduction in agoraphobic avoidance. Expand
...
1
2
3
4
5
...